SOLIGENIX, INC. Interest Income (Expense), Nonoperating, Net
SOLIGENIX, INC. (SNGX) reported Interest Income (Expense), Nonoperating, Net of $53.60 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-07
- SOLIGENIX, INC. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $53.60K, a 23.24% decline year-over-year.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $61.39K, a 19.25% decline year-over-year.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $71.97K, a 2.27% increase year-over-year.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $52.35K, a 33.60% decline year-over-year.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for fiscal 2025 was $270.17K, a 26.26% increase from fiscal 2024.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for fiscal 2024 was $213.97K.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for fiscal 2023 was -$49.13K.
- SOLIGENIX, INC. interest income (expense), nonoperating, net for fiscal 2022 was -$822.61K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.60K 10-Q · filed 2026-08-07 | $114.99K 10-Q · filed 2026-08-07 | $186.96K derived: sum of 3 quarters · filed 2026-08-07 | $239.31K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $61.39K 10-Q · filed 2026-05-08 | $133.36K derived: sum of 2 quarters · filed 2026-05-08 | $185.71K derived: sum of 3 quarters · filed 2026-05-08 | $255.53K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $71.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $124.32K derived: sum of 2 quarters · filed 2026-03-31 | $194.14K derived: sum of 3 quarters · filed 2026-08-07 | $270.17K 10-K · filed 2026-03-31 |
| 2025-09-30 | $52.35K 10-Q · filed 2025-11-07 | $122.17K derived: sum of 2 quarters · filed 2026-08-07 | $198.20K 10-Q · filed 2025-11-07 | $268.57K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $69.82K 10-Q · filed 2026-08-07 | $145.85K 10-Q · filed 2026-08-07 | $216.22K derived: sum of 3 quarters · filed 2026-08-07 | $295.06K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $76.03K 10-Q · filed 2026-05-08 | $146.40K derived: sum of 2 quarters · filed 2026-05-08 | $225.24K derived: sum of 3 quarters · filed 2026-05-08 | $261.16K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $70.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $149.21K derived: sum of 2 quarters · filed 2026-03-31 | $185.13K derived: sum of 3 quarters · filed 2026-03-31 | $213.97K 10-K · filed 2026-03-31 |
| 2024-09-30 | $78.84K 10-Q · filed 2025-11-07 | $114.76K derived: sum of 2 quarters · filed 2025-11-07 | $143.60K 10-Q · filed 2025-11-07 | $191.87K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $35.92K 10-Q · filed 2025-08-14 | $64.77K 10-Q · filed 2025-08-14 | $113.04K derived: sum of 3 quarters · filed 2025-08-14 | $179.40K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $28.84K 10-Q · filed 2025-05-09 | $77.11K derived: sum of 2 quarters · filed 2025-05-09 | $143.47K derived: sum of 3 quarters · filed 2025-05-09 | $83.28K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $48.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $114.63K derived: sum of 2 quarters · filed 2025-03-21 | $54.44K derived: sum of 3 quarters · filed 2025-03-21 | -$49.13K 10-K · filed 2025-03-21 |
| 2023-09-30 | $66.36K 10-Q · filed 2024-11-08 | $6.17K derived: sum of 2 quarters · filed 2024-11-08 | -$97.40K 10-Q · filed 2024-11-08 | -$278.24K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$60.19K 10-Q · filed 2024-08-09 | -$163.76K 10-Q · filed 2024-08-09 | -$344.61K derived: sum of 3 quarters · filed 2024-08-09 | -$559.75K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$103.57K 10-Q · filed 2024-05-10 | -$284.41K derived: sum of 2 quarters · filed 2024-05-10 | -$499.56K derived: sum of 3 quarters · filed 2024-05-10 | -$714.47K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$180.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$395.99K derived: sum of 2 quarters · filed 2024-03-15 | -$610.90K derived: sum of 3 quarters · filed 2024-03-15 | -$822.61K 10-K · filed 2024-03-15 |
| 2022-09-30 | -$215.15K 10-Q · filed 2023-11-13 | -$430.05K derived: sum of 2 quarters · filed 2023-11-13 | -$641.77K 10-Q · filed 2023-11-13 | -$869.76K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$214.91K 10-Q · filed 2023-08-21 | -$426.62K 10-Q · filed 2023-08-21 | -$654.61K derived: sum of 3 quarters · filed 2023-08-21 | -$881.88K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$211.71K 10-Q · filed 2023-05-15 | -$439.70K derived: sum of 2 quarters · filed 2023-05-15 | -$666.98K derived: sum of 3 quarters · filed 2023-05-15 | -$902.71K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$227.99K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$455.26K derived: sum of 2 quarters · filed 2023-03-31 | -$691.00K derived: sum of 3 quarters · filed 2023-03-31 | -$904.50K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$227.27K 10-Q · filed 2022-11-10 | -$463.01K derived: sum of 2 quarters · filed 2022-11-10 | -$676.51K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$235.74K 10-Q · filed 2022-08-12 | -$449.24K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |